ScreenerHero

FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

NAS · US · Healthcare · Biotechnology · fortressbiotech.com
16.65USD-1.07%Mkt Cap: —P/E: —

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap—
Enterprise Value518.35M USD
Revenue (TTM)68.47M USD
Gross Profit42.34M USD
Net Income (TTM)6.82M USD
Revenue/Share2.25 USD
Last Price16.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-20.75
EV/Revenue7.57
P/S—
P/B3.77
EPS (TTM)-0.86
EPS (Forward)—
52W Range
6.27068% of range21.43
52W High21.43 USD
52W Low6.270 USD
Profitability
Gross Margin66.92%
Oper. Margin-53.46%
EBITDA Margin-36.48%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth14.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M USD
CapEx (TTM)—
FCF Margin-25.03%
FCF Yield—
Net Debt-143.26M USD
Net Debt/EBITDA5.74
Balance Sheet
Debt/Equity1.49
Current Ratio3.96
Quick Ratio3.76
Book Value/Sh4.93 USD
Cash/Share5.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield12.09%
Payout Ratio—
Ex-Div DateJun 14, 2024
Pay DateJun 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.56.68M
Float21.44M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.0d
Shares Short0
Short (prev mo.)710
Technical
SMA 5018.28 (-8.9%)
SMA 20015.61 (+6.6%)
Beta1.25
S&P 52W Chg15.78%
Avg Vol (30d)11.98K
Avg Vol (10d)24.87K
Technical Indicators
RSI (14)22.0
MACD-0.5202
MACD Signal-0.3430
MACD Hist.-0.1772
BB Upper19.40 USD
BB Middle18.05 USD
BB Lower16.70 USD
BB Width14.99%
ATR (14)0.4228 USD
Vol Ratio (20d)6.60x